title: Treatment of acute promyelocytic leukemia with high white cell blood counts.
abstract: Acute promyelocytic leukemia (APL) with WBC above 10 G/L has long been considered, even in the all-trans retinoic acid (ATRA) era, to carry a relatively poor prognosis (compared to APL with WBC below 10 G/L), due to increased early mortality and relapse. However, early deaths can to a large extent be avoided if specific measures are rapidly instigated, including prompt referral to a specialized center, immediate onset of ATRA and chemotherapy, treatment of coagulopathy with adequate platelet transfusional support, and prevention and management of differentiation syndrome. Strategies to reduce relapse rate include chemotherapy reinforcement with cytarabine and/or arsenic trioxide during consolidation, prolonged maintenance treatment, especially with ATRA and low dose chemotherapy, and possibly, although this is debated, intrathecal prophylaxis to prevent central nervous system relapse. By applying those measures, outcomes of patients with high risk APL have considerably improved, and have become in many studies almost similar to those of standard risk APL patients.
authors.affiliation: Department of Hematology, G. Papanikolaou Hospital of Thessaloniki, Exochi 57010, Greece.
authors.forename: C
authors.initials: C
authors.lastname: Kelaidi
authors.forename: L
authors.initials: L
authors.lastname: Adès
authors.forename: P
authors.initials: P
authors.lastname: Fenaux
references.citation: Blood. 2011 Feb 10;117(6):1799-805
references.pmid: 21148082
references.citation: Blood. 2008 Apr 1;111(7):3395-402
references.pmid: 18195095
references.citation: Blood. 2008 Oct 15;112(8):3130-4
references.pmid: 18664623
references.citation: Blood. 2011 Aug 4;118(5):1248-54
references.pmid: 21653939
references.citation: Blood. 2010 Jun 24;115(25):5137-46
references.pmid: 20393132
references.citation: J Clin Oncol. 2009 Feb 1;27(4):504-10
references.pmid: 19075265
references.citation: J Clin Oncol. 2004 Apr 15;22(8):1404-12
references.pmid: 15084614
references.citation: Br J Haematol. 2011 Jan;152(1):89-98
references.pmid: 20735397
references.citation: Blood. 2002 Nov 1;100(9):3141-6
references.pmid: 12384411
references.citation: Nouv Rev Fr Hematol (1978). 1984;26(6):371-8
references.pmid: 6597407
references.citation: Br J Haematol. 1976 Aug;33(4):451-8
references.pmid: 188440
references.citation: Br J Haematol. 2000 Mar;108(4):689-95
references.pmid: 10792270
references.citation: J Clin Oncol. 2009 Aug 1;27(22):3650-8
references.pmid: 19506161
references.citation: J Clin Oncol. 2011 Jul 10;29(20):2753-7
references.pmid: 21646615
references.citation: J Clin Oncol. 2006 Dec 20;24(36):5703-10
references.pmid: 17116939
references.citation: Blood. 1998 Oct 15;92(8):2712-8
references.pmid: 9763554
references.citation: Haematologica. 2010 May;95(5):853-4
references.pmid: 20015875
references.citation: Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5328-35
references.pmid: 15044693
references.citation: Blood. 2005 Jul 15;106(2):447-53
references.pmid: 15677559
references.citation: Leukemia. 2003 Jun;17(6):1085-90
references.pmid: 12764372
references.citation: Blood. 2010 Mar 4;115(9):1697-702
references.pmid: 20029047
references.citation: Leuk Lymphoma. 1991;4(4):239-48
references.pmid: 27463043
references.citation: Ann Intern Med. 1992 Aug 15;117(4):292-6
references.pmid: 1637024
references.citation: Blood. 2008 Feb 1;111(3):1078-84
references.pmid: 17975017
references.citation: Blood. 2010 Oct 28;116(17):3171-9
references.pmid: 20644121
references.citation: Blood. 2010 Nov 11;116(19):3751-7
references.pmid: 20705755
references.citation: Blood. 2009 Jan 22;113(4):775-83
references.pmid: 18945964
references.citation: J Clin Oncol. 2010 Feb 20;28(6):1047-53
references.pmid: 20085935
references.citation: Leukemia. 2005 Jul;19(7):1153-60
references.pmid: 15889156
references.citation: J Clin Oncol. 2009 Jun 1;27(16):2668-76
references.pmid: 19414681
references.citation: Blood. 1999 Aug 15;94(4):1192-200
references.pmid: 10438706
references.citation: Leukemia. 2009 Dec;23(12):2248-58
references.pmid: 19741727
references.citation: J Clin Oncol. 2010 Aug 20;28(24):3866-71
references.pmid: 20644086
references.citation: Blood. 1988 Aug;72(2):567-72
references.pmid: 3165295
references.citation: Blood. 2010 Mar 4;115(9):1690-6
references.pmid: 20018913
references.citation: Haematologica. 2009 Sep;94(9):1242-9
references.pmid: 19608685
references.citation: Blood. 2000 Aug 15;96(4):1247-53
references.pmid: 10942364
references.citation: Blood. 2009 Feb 26;113(9):1875-91
references.pmid: 18812465
references.citation: J Clin Oncol. 1998 Jan;16(1):78-85
references.pmid: 9440726
references.citation: J Clin Oncol. 2005 Oct 20;23(30):7632-40
references.pmid: 16234524
references.citation: Cell. 1991 Aug 23;66(4):675-84
references.pmid: 1652369
references.citation: Am J Med. 1984 May;76(5):827-41
references.pmid: 6586073
references.citation: J Clin Oncol. 2012 May 10;30(14):1641-6
references.pmid: 22473162
references.citation: Leukemia. 2005 Feb;19(2):230-3
references.pmid: 15565164
references.citation: Blood. 2004 Dec 1;104(12):3490-3
references.pmid: 15292063
references.citation: Cell. 1991 Aug 23;66(4):663-74
references.pmid: 1652368
references.citation: Blood. 1990 Nov 1;76(9):1704-9
references.pmid: 2224119
references.citation: Blood. 1989 Apr;73(5):1116-22
references.pmid: 2930837
references.citation: Blood. 1999 Oct 1;94(7):2225-9
references.pmid: 10498592
references.citation: Cancer. 1988 Jan 1;61(1):7-13
references.pmid: 3422032
references.citation: Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3342-7
references.pmid: 19225113
references.citation: Leukemia. 2006 Jan;20(1):35-41
references.pmid: 16307026